Zelluna ASA
Sector unknown·ZLNA · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Biotech and drug development
Technology
DriverNegative impact: weakens
“Risks and uncertainties Risks identified in relation to the Business Combination with Zelluna Immunotherapy AS As part of the work of preparing the Business Combination with Zelluna Immunotherapy AS ("ZI"), the following main risk factors have been identified: Material risk factors related to Zelluna Immunotherapy AS ZI is in an early stage of development and its preclinical and/or clinical studies may not prove to be successful.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Zelluna’s TCR-NK products are in preclinical development, with the goal of advancing into Phase I/II trials to evaluate the safety and efficacy of its treatments for advanced solid tumours.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Due to negative outcomes in three of the phase II trials, the UV1 cancer vaccine programme will be wrapped up.”
Annual report 2024A · The company itself
Chains in: US drug pricing policy mixed effect, Patent expiry and generic competition weakens, Drug approvals strengthens
Chains out: this strengthens Buying contract manufacturing and research (CMO/CRO/EMS), strengthens Contract manufacturers as a business (EMS, CMO, CRO)
Equity and capital markets
Macro
DriverNegative impact: weakens
“ZI will require additional financing to execute its strategy, but adequate sources of funding may not be available when needed or may not be available on favourable terms.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“It is believed that the combined company can leverage Zelluna ASA’s established clinical development capabilities and public listing status to take Zelluna Immunotherapy AS' novel and proprietary cell therapy platform and pipeline to the clinic.”
Annual report 2024A · The company itself
Gene and cell therapy
Technology
StrategyPositive impact: strengthens
“Strategic Shift Post-Business Combination Following the business combination with Zelluna Immunotherapy AS, the Company is prioritizing the de-velopment of Zelluna Immunotherapy AS’s proprietary TCR-NK cell therapy platform. The strategic focus is now on i.) advancing the world's first MAGE-A4 targeting TCR-NK program, ZI-MA4-1, into first-in-hu-man clinical studies treating solid cancers, ii.) developing the TCR-NK pipeline, and iii.) seeking to unlock the MultiClick technology potential.”
Annual report 2024A · The company itself
Market
“Zelluna is a biotech company whose mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).”
Annual report 2024A · The company itself
Market
“Zelluna is developing a novel allogeneic cell therapy platform combining Natural Killer ("NK") cells with tumour specific T cell receptors ("TCRs") ("TCR-NK"). The TCR-NK products are composed of healthy donor derived NK cells that are genetically engineered to express a tumour specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient.”
Annual report 2024A · The company itself
Market
“The lead asset nearing the clinic is a world’s first MAGE-A4 targeting TCR-NK which can potentially be used to treat a range of solid cancers with unmet medical need in high value cancer markets.”
Annual report 2024A · The company itself
Market
“The combined company will mainly focus on Zelluna Immunotherapy AS’s technology and research pipeline, specifically the development of “off-the-shelf” T-Cell Receptor Natural Killer (TCR-NK) cell therapies for the treatment of a range of solid cancers and wrap up the UV1 program.”
Annual report 2024A · The company itself
Market
“Specifically, cell therapies are a class of therapeutics that have delivered “cures” in late-stage cancer patients with 9 therapies currently market approved mainly for liquid cancers and several with data from fewer than 100 patients for regulatory approval.”
Annual report 2024A · The company itself
Automation and robotics
Technology
StrategyPositive impact: strengthens
“TCR-NK cells can be manufactured upfront at a large scale and shipped to patients on demand, enabling scalability to a large patient population.”
Annual report 2024A · The company itself
Buying contract manufacturing and research (CMO/CRO/EMS)
Raw materials and inputs
InputNegative impact: weakens
“Manufacturing of cell therapies is highly complex and ZI relies, and will continue to rely, upon third parties for process development and manufacturing of its cell therapy products, and supply of essential materials.”
Annual report 2024A · The company itself
InputNegative impact: weakens
“FTEs employed during the financial year 2024, and 12 FTEs per 31.12.2024 Main suppliers: Suppliers manufacturing drug products (Corden Pharma, PolyPeptide), research contract organizations (Lab- Corp), hospitals and other organizations conducting clinical studies (Nordic Society of Gynecological Oncology (NSGO), Oslo Universitetssykehus (OUS), Universitätsklinikum Halle).”
Annual report 2024A · The company itself
Chains in: Biotech and drug development strengthens
Labour and wages
Raw materials and inputs
InputNegative impact: weakens
“FTEs employed during the financial year 2024, and 12 FTEs per 31.12.2024 Main suppliers: Suppliers manufacturing drug products (Corden Pharma, PolyPeptide), research contract organizations (Lab- Corp), hospitals and other organizations conducting clinical studies (Nordic Society of Gynecological Oncology (NSGO), Oslo Universitetssykehus (OUS), Universitätsklinikum Halle).”
Annual report 2024A · The company itself
M&A and consolidation
Macro
DriverNegative impact: weakens
“The biopharmaceutical industry is characterized by rapidly advancing technologies and ZI's technology and product candidates may be out-competed or rendered obsolete by ZI's competitors.”
Annual report 2024A · The company itself
Europe
Geography
Geography
“UV1 was Ultimovacs’ lead universal cancer vaccine candidate, and during 2024, Ultimovacs conducted a broad clinical development program for UV1 with clinical trials in Europe, Australia, and the USA.”
Annual report 2024A · The company itself
Nordics
Geography
Geography
“Zelluna ASA has a fully owned Swedish subsidiary located in Uppsala, Ultimovacs AB, and together they are defined as the 'Group' for 2024.”
Annual report 2024A · The company itself
United States
Geography
Geography
“UV1 was Ultimovacs’ lead universal cancer vaccine candidate, and during 2024, Ultimovacs conducted a broad clinical development program for UV1 with clinical trials in Europe, Australia, and the USA.”
Annual report 2024A · The company itself
Chains in: USD vs DKK/EUR mixed effect
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0 bn NOK |
| Revenue growth vs. the year before, same method | N/A |
| EBITDA reported by the company | -0.22 bn NOK |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | -5.8 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | N/A |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.